Abivax SA (ABVX) vs Ionis Pharmaceuticals (IONS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Abivax SA (ABVX) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 0.0% versus a loss of 35.9%. Abivax SA is the larger company by market cap ($7.59 billion vs $7.34 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | IONS |
|---|---|---|
| Share price | $87.01 | $44.16 |
| Market cap | $7.59B | $7.34B |
| 1-day change | -1.37% | +0.36% |
| YTD return | -35.48% | -44.18% |
| 1-year return | 0.00% | -35.94% |
| 5-year return | — | +25.81% |
| EPS (TTM) | $-6.00 | $-3.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $943.71M |
| Revenue growth (YoY) | — | +33.83% |
| Net income (latest FY) | — | $-381.39M |
| Gross margin | — | 98.31% |
| Operating margin | — | -40.45% |
| Net margin | — | -40.41% |
| 52-week high | $148.83 | $86.74 |
| 52-week low | $69.81 | $42.63 |
| Distance from 52-week high | -41.54% | -49.09% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +88.48% | +89.40% |
| Average volume | 1.09M | 3.79M |
| Shares outstanding | 87.27M | 166.18M |
| Employees | 98 | 1,480 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABVX has outperformed IONS by 35.9 percentage points over the past year.
- The two companies sit in different sectors: Abivax SA in Health Care and Ionis Pharmaceuticals in Healthcare.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Healthcare · Biotechnology · 1,480 employees
ABVX vs IONS FAQ
Which is bigger, Abivax SA or Ionis Pharmaceuticals?
Abivax SA (ABVX) is larger, with a market capitalization of $7.59B compared with $7.34B for Ionis Pharmaceuticals (IONS).
Which stock has performed better over the past year, ABVX or IONS?
ABVX returned 0.00% over the past 12 months, compared with -35.94% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Ionis Pharmaceuticals in the same industry?
No. Abivax SA is in the Health Care sector, while Ionis Pharmaceuticals is in Healthcare.